Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 20/20 | 0.74 |
| ▸ | NR1I2 | O75469 | 10/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3035462 | 0.93 | CACNA1B (0.78) | CACNA1BNR1I2CYP3A4 | |
| SCHEMBL3025559 | 0.91 | CACNA1B (0.86) | CACNA1BNR1I2CYP3A4 | |
| SCHEMBL3039575 | 0.91 | CACNA1B (0.74) | CACNA1BNR1I2CYP3A4 | |
| SCHEMBL3036257 | 0.91 | CACNA1B (0.74) | CACNA1BNR1I2CYP3A4 | |
| SCHEMBL3039947 | 0.90 | CACNA1B (0.73) | CACNA1BNR1I2CYP3A4 | |
| SCHEMBL3032185 | 0.90 | CACNA1B (0.73) | CACNA1BNR1I2CYP3A4 | |
| SCHEMBL3031675 | 0.88 | CACNA1B (0.70) | CACNA1BNR1I2CYP3A4 | |
| SCHEMBL3030335 | 0.88 | CACNA1B (0.81) | CACNA1BNR1I2CYP3A4 | |
| SCHEMBL3032937 | 0.87 | CACNA1B (0.75) | CACNA1BNR1I2CYP3A4 | |
| SCHEMBL3035409 | 0.87 | CACNA1B (0.69) | CACNA1BNR1I2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040932-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040932-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TRPV1, TRPA1, CACNA1D | CACNA1B 23/4885NR1I2 765/4885CYP3A4 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.